⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Obsidian Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Obsidian Therapeutics
↗Cambridge, Massachusetts, USA
Obsidian Therapeutics is a clinical-stage biopharmaceutical company pioneering engineered cell and gene therapies. The company utilizes its proprietary cytoDRiVE® platform to develop tumor-infiltrating lymphocyte (TIL) cell therapies that allow for precise, pharmacologic control of protein activity, aiming to improve efficacy and safety in the treatment of solid tumors.
In April 2026, Obsidian announced a definitive merger agreement with Galera Therapeutics to become a publicly traded company under the name Obsidian Therapeutics, Inc., with plans to trade on Nasdaq under the ticker 'OBX'. The merger is supported by a $350 million concurrent private placement to fund clinical operations through 2028.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$25M-$50M
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$350M
Investors:Balyasny Asset Management
STOCK
Exchange:NASDAQ
Ticker:OBX
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Cell therapy, Gene therapy
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Galera Therapeutics (Merger)
COMPETITION
Position:Emerging
Competitors:Iovance Biotherapeutics, Phio Pharmaceuticals
LEADERSHIP
Key Executives:
Madan Jagasia - CEO
Dana Alexander - CTO
Jeffrey Trigilio - CFO
Scientific Founders:Thomas Wandless
Board Members:Matthew Norkunas
LINKS
Website:obsidiantx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Obsidian Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.